Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,693 result(s) found for: placebo. Displaying page 6 of 635.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2006-003509-18 Sponsor Protocol Number: NAC0606 Start Date*: 2007-08-13
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian Health Board
    Full Title: Mechanisms for the effect of acetylcysteine on renal function after exposure to radiographic contrast material
    Medical condition: Radiocontrast-induced nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022110-29 Sponsor Protocol Number: SG006 Start Date*: 2010-10-08
    Sponsor Name:Synairgen Research Limited
    Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in...
    Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001436-22 Sponsor Protocol Number: 2012CV07 Start Date*: 2013-08-06
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study
    Medical condition: Renal failure and left ventricular hypertrophy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017415-16 Sponsor Protocol Number: AFCT-14/2009 Start Date*: 2010-07-26
    Sponsor Name:Dr. August Wolff GmbH & Co KG Arzneimittel
    Full Title: A Phase III, single-center, randomized, double-blind, parallel group, placebo-controlled study of Alpicort F in the treatment of chemotherapy induced alopecia in women
    Medical condition: Chemotherapy induced alopecia in women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001620-21 Sponsor Protocol Number: CL_700_001_PRO Start Date*: 2004-11-23
    Sponsor Name:LAB Pharma Ltd
    Full Title: A multicentre, multinational, randomised, double blind, single dummy, parallel group, placebo-controlled trial to investigate the dose-response and safety of Fentanyl TAIFUN 100 µg, 200 µg, 400 µg ...
    Medical condition: Patients with cancer having episodes of breakthrough pain.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058019 canc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) LV (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001544-11 Sponsor Protocol Number: 109216 Start Date*: 2015-06-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated huma...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002185-13 Sponsor Protocol Number: clebopride2019 Start Date*: 2019-10-03
    Sponsor Name:KU Leuven - TARGID
    Full Title: A Randomized, Double Blind, Placebo Controlled, Crossover Trial of Clebopride vs Placebo in the Treatment of Clinically Suspected Rumination.
    Medical condition: rumination syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003932-35 Sponsor Protocol Number: BIO101-CL03 Start Date*: 2018-02-20
    Sponsor Name:Biophytis S.A.
    Full Title: Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week oral administration to patients suffering from age-related SARcopenia, including sarcopenic obesity, Aged ≥65 years and at ris...
    Medical condition: Sarcopenia including sarcopenic obesity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10028395 - Musculoskeletal and connective tissue disorders 10063024 Sarcopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001933-11 Sponsor Protocol Number: 73828-041-20 Start Date*: 2021-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome
    Medical condition: Primary Sjogren Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004685-10 Sponsor Protocol Number: PD-1105 Start Date*: 2019-01-11
    Sponsor Name:Voyager Therapeutics, Inc.
    Full Title: A Randomized, Placebo Surgery Controlled, Double-blinded, Multi-center, Phase 2 Clinical Trial, Evaluating the Efficacy and Safety of VY-AADC02 in Advanced Parkinson's Disease With Motor Fluctuatio...
    Medical condition: Patients with Parkinson's Disease with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003737-29 Sponsor Protocol Number: BUU-5/EEA Start Date*: Information not available in EudraCT
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophi...
    Medical condition: Active eosinophilic esophagitis and maintenance of remission in eosinophilic esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10064220 Eosinophilic esophagitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) PT (Completed) NL (Completed) GR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001853-15 Sponsor Protocol Number: NL61830 Start Date*: 2018-07-11
    Sponsor Name:Leiden University Medical Center
    Full Title: An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells.
    Medical condition: Pulmonary emphysema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003983-30 Sponsor Protocol Number: CPH-303-201400 Start Date*: 2019-05-22
    Sponsor Name:Croma-Pharma GmbH
    Full Title: Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10052609 Glabellar frown lines LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004409-24 Sponsor Protocol Number: AK130940 Start Date*: 2005-06-08
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150m...
    Medical condition: Major Depressive Disorder (MDD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004521-32 Sponsor Protocol Number: D5780C00007 Start Date*: 2018-08-22
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003227-20 Sponsor Protocol Number: ZD4054 Start Date*: 2007-09-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free...
    Medical condition: hormone-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Prematurely Ended) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) NL (Completed) FR (Completed) PT (Completed) DK (Prematurely Ended) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004944-37 Sponsor Protocol Number: MK-3475-054-07 Start Date*: 2015-09-22
    Sponsor Name:Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc
    Full Title: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial o...
    Medical condition: Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2011-004771-36 Sponsor Protocol Number: IC43-202 Start Date*: 2012-01-19
    Sponsor Name:Valneva Austria GmbH
    Full Title: A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.
    Medical condition: Nosocomial Pseudomonas aeruginosa infections in mechanically ventilated ICU patients
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10061471 Pseudomonas infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) HU (Completed) ES (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-004670-24 Sponsor Protocol Number: SYR-322-PLC-010 Start Date*: 2006-05-26
    Sponsor Name:Takeda Global Research & Development Center, Inc.
    Full Title: A multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-000539-27 Sponsor Protocol Number: CLAF237A2307 Start Date*: 2004-09-08
    Sponsor Name:Novartis Sverige AB
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperg...
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 06 16:53:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA